載入中
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
一般交易時段
US$1.135
−US$0.125 · -9.92%
盤中時間採用ET。市場資料可能有所延遲。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日內區間
目前US$1.135
52週區間
目前US$1.135
盤中時間採用ET。市場資料可能有所延遲。
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
日內區間
目前US$1.135
52週區間
目前US$1.135
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 7699.6萬 USD | 1.16億 USD | 1.42億 USD | 9840萬 USD | 6017萬 USD |
| 銷售、一般及管理費用 | 2385萬 USD | 2609.4萬 USD | 2848.3萬 USD | 2903.6萬 USD | 2338.5萬 USD |
| 營業費用 | 1.04億 USD | 1.42億 USD | 1.7億 USD | 1.27億 USD | 8355.5萬 USD |
| 利息收入 | 396.4萬 USD | 936.6萬 USD | 1064.9萬 USD | 427.8萬 USD | 91 USD |
| 利息支出 | 160.2萬 USD | 172.9萬 USD | 156.5萬 USD | 23.8萬 USD | 1.3萬 USD |
| 折舊和攤銷 | 70.6萬 USD | 87.2萬 USD | 83.6萬 USD | 34.2萬 USD | 5.1萬 USD |
| 營業利益 | −1.04億 USD | −1.42億 USD | −1.7億 USD | −1.27億 USD | −8355.5萬 USD |
| 淨利 | −1.02億 USD | −1.35億 USD | −1.61億 USD | −1.23億 USD | −8346.3萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$17.90
上漲空間 1477.09%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI703.07萬0.00%2.3兆 USD0.03%US$380.62-0.25%
iShares Russell 2000 ETFIWM325.9萬0.00%787.4億 USD0.19%US$276.02-0.68%
Vanguard Extended Market ETFVXF236.63萬0.00%954億 USD0.05%US$231.59-0.83%
Vanguard Russell 2000 ETFVTWO119.96萬0.01%180億 USD0.06%US$111.48-0.71%
iShares Russell 2000 Growth ETFIWO115.65萬0.01%139.17億 USD0.24%US$350.52-0.90%
iShares Micro-Cap ETFIWC38.67萬0.03%13.17億 USD0.60%US$179.92-0.96%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM26萬0.23%1.16億 USD0.73%US$15.71-0.87%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC23.56萬0.02%10.47億 USD0.20%US$85.785-0.55%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
